Vor Bio Completes Enrollment in Phase 3 MG Trial, Expands Telitacicept into Ocular MG
VOR has more than doubled off its 52-week low of $6.5 on light trading volume (0.4× avg).
Summary
Vor Bio completed enrollment in UPSTREAM MG, its global Phase 3 trial of telitacicept for generalized myasthenia gravis, with topline data still expected in H1 2027. The company also announced plans to initiate UPSTREAM oMG, a separate Phase 3 trial in ocular myasthenia gravis, with first patient dosing anticipated in H1 2027. This expansion broadens the telitacicept franchise across the MG spectrum and builds on positive Phase 3 data from RemeGen in China. The news follows a recent S-3ASR shelf filing and a 10-Q that disclosed a going concern warning, so clinical execution remains critical. Investors will focus on the H1 2027 readout as the next major catalyst.
At the time of this announcement, VOR was trading at $24.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $6.50 to $49.95. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.